49P Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation

In subgroup analyses of EMPOWER-Lung 1, a randomised 1:1 open-label phase III study, improvement in overall survival (OS) with CEMI (n = 48) vs CHEMO 47) (median OS: not reached 7.4 months; HR: 0.38; 95% confidence interval [CI]: 0.19, 0.75) was observed patients aNSCLC PD-L1 ≥ 50% and baseline liver metastases. this post hoc analysis, we evaluated PROs. PROs were assessed at Day 1 each treatment cycle for the first 6 cycles, then on every third using European Organisation Research Treatment Cancer Quality Life-Core 30 (QLQ-C30) Lung 13 (QLQ-LC13) questionnaires. Higher scores indicate better functioning global health status (GHS)/quality life (QoL) or worse symptom severity. Mixed-effects repeated-measures used to compare change from between arms, controlling other covariates. Statistically significant difference physical favoured (6.24; CI: 0.34, 12.14; P 0.0384). also resulted statistically favourable symptoms nausea/vomiting (–3.80; –7.29, –0.31; 0.0334), alopecia (–15.75; –24.61, –6.88; 0.0007) pain arm shoulder (–9.05; –16.67, –1.43; 0.0208). Compared CHEMO, had numerically improved GHS/QoL, all scales, 15 18 scales. No yielded PRO results favouring any QLQ-C30 QLQ-LC13 ≥50% metastases, functioning, nausea/vomiting, CHEMO. further support benefit-risk profile first-line